Sabri Jamal
A5071763098- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Mechanisms of cancer metastasis
- Chromatin Remodeling and Cancer
- Neuroblastoma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Single-cell and spatial transcriptomics
- Computational Drug Discovery Methods
- Pancreatic and Hepatic Oncology Research
- Tumors and Oncological Cases
- Childhood Cancer Survivors' Quality of Life
- BRCA gene mutations in cancer
- Estrogen and related hormone effects
- Salivary Gland Tumors Diagnosis and Treatment
- Gene expression and cancer classification
- Cancer Cells and Metastasis
- Animal Genetics and Reproduction
- AI in cancer detection
Institute of Cancer Research
2019-2024
Royal Marsden NHS Foundation Trust
2021-2024
Royal Marsden Hospital
2019-2024
Breast Cancer Now
2023
Uppsala University
2018
PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion status, no genomic markers are available risk stratification. We present an international consortium study designed to determine incidence driver mutations their association clinical outcome. PATIENTS AND METHODS Tumor samples collected from enrolled on Children's Oncology...
Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast evolves with time and under selective pressure treatment, potential acquire mutations resistance treatment disease progression. To identify potentially targetable in advanced cancer, we performed prospective characterization a cohort patients ABC.Biopsies from were sequenced 41 genes targeted panel ABC Biopsy (ABC-Bio) study. Blood samples collected at progression for...
Coral reefs are colored by eukaryotic chromoproteins (CPs) that homologous to green fluorescent protein. CPs differ from proteins (FPs) intensely absorbing visible light give strong colors in ambient light. This endows with certain advantages over FPs, such as instrument-free detection uncomplicated ultra-violet damage or background fluorescence, efficient Förster resonance energy transfer (FRET) quenching, and photoacoustic imaging. Thus, have found utility genetic markers teaching,...
BackgroundFor children with cancer, the clinical integration of precision medicine to enable predictive biomarker–based therapeutic stratification is urgently needed.MethodsWe have developed a hybrid-capture next-generation sequencing (NGS) panel, specifically designed detect genetic alterations in paediatric solid tumours, which gives reliable results from as little 50 ng DNA extracted formalin-fixed paraffin-embedded (FFPE) tissue. In this study, we offered an NGS reporting via molecular...
<div>Abstract<p>We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed progressive solid tumors childhood. Tissue cfDNA sequencing results were concordant, wider spectrum mutant alleles higher degree intratumor heterogeneity captured by the latter, if sufficient ctDNA was present. Serial identified putative drivers relapse, alterations in epigenetic being common feature. In...
<p>Proportion of patients with genetic aberrations.</p>
<p>Concordance between ctDNA and tissue copy number profiles.</p>
<p>Similarity matrix for TFBS sets.</p>
<p>Cohort-wide oncoplot for tissue vs cfDNA variants.</p>
<p>Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.</p>
<p>STRINGDB interaction networks of disease-specific fragmentomics clusters.</p>
<p>Primary vs. relapse copy number profiles.</p>
<p>Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.</p>
<p>Top relapse-specific copy number events.</p>
<p>Disease-specific diagnostic vs. relapse sequence variants.</p>
<p>Fraction of genome altered by disease group.</p>
<p>Disease-specific cfDNA vs. tissue sequence variants.</p>